AstraZeneca PLC’s Imfinzi (durvalumab) could be poised for expanded use in the big first-line metastatic non-small cell lung cancer market now that, at long last, a trial testing the PD-L1 inhibitor with AstraZeneca’s CTLA-4 antibody tremelimumab in first-line NSCLC met the primary endpoint of improvement in progression-free survival.
The company released the top-line results of the Phase III POSEIDON trial on 28 October, but the trial is continuing...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

